
CLAIMS

We claim:

1. A compound of Formula (Ia)



(Ia)

or a pharmaceutically acceptable salt thereof, wherein:

A is a 4 to 7 membered monocyclic heterocyclyl saturated or partially unsaturated and optionally substituted with 1 to 5 R^3 groups;

each R^3 is independently selected from the group consisting of C_{1-4}alkyl, halogen and oxo; or two R^3 connected to the same or adjacent carbon atoms form a spiro or fused C_{3-6}cycloalkyl or 4 to 6 membered heterocyclyl ring;

A' is selected from the group consisting of C_{3-7} monocyclic cycloalkyl and 4 to 7 membered monocyclic heterocyclyl; wherein each C_{3-7} monocyclic cycloalkyl and 4 to 7 membered monocyclic heterocyclyl is optionally substituted with 1 to 5 R^4 groups;

each R^4 is independently selected from the group consisting of C_{1-4}alkyl, halogen and oxo; or two R^4 connected to the same or adjacent carbon atoms form a spiro or fused C_{3-6}cycloalkyl or 4 to 6 membered heterocyclyl ring;

R^1 is phenyl optionally substituted with 1 to 5 R^5 groups;

each R^5 is independently selected from the group consisting of halogen and C_{1-3}alkyl; and

R^2 is selected from the group consisting of H, C_{1-3}haloalkyl and C_{1-4}alkyl.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a 5 or 6 membered monocyclic heterocyclyl saturated or partially unsaturated and optionally substituted with 1 to 5 R^3 groups.


3. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of oxazolidinyl,



piperidinyl, 3,4-unsaturated piperidinyl, pyrrolidinyl, tetrahydro-1,3-oxazinyl and thiazolidinyl; each of which is optionally substituted with 1 to 5 R^3 groups.


4. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of oxazolidinyl, piperidinyl, 3,4-unsaturated piperidinyl, pyrrolidinyl, tetrahydro-1,3-oxazinyl and thiazolidinyl; each of which is optionally substituted with one or two R^3 groups; wherein R^3 is $C_{1\text{-}4}$alkyl; or two R^3 connected to the same or adjacent carbon atoms form a spiro or fused $C_{3\text{-}6}$cycloalkyl or 4 to 6 membered heterocyclyl ring.


5. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of oxazolidinyl, piperidinyl, 3,4-unsaturated piperidinyl, pyrrolidinyl, tetrahydro-1,3-oxazinyl and thiazolidinyl; each of which is optionally substituted with methyl.

6. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein  is selected from the group consisting of:



 and .

7. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein  is selected from the group consisting of:



and .

8. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A' is selected from the group consisting of C_{5-6} monocyclic cycloalkyl and 5 to 6 membered monocyclic heterocyclyl; wherein each C_{5-6} monocyclic cycloalkyl and 5 to 6 membered monocyclic heterocyclyl is optionally substituted with 1 to 5 R^4 groups.


9. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A' is selected from the group consisting of cyclopentyl, tetrahydrofuranyl, cyclohexyl and tetrahydropyranyl; each of which is optionally substituted with 1 to 5 R^4 groups.


10. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A' is selected from the group consisting of cyclopentyl, tetrahydrofuranyl, cyclohexyl and tetrahydropyranyl; each of which is optionally substituted with one or two R^4 groups, wherein each R^4 is independently selected from the group consisting of C_{1-4}alkyl, halogen and oxo; or two R^2 connected to the same or adjacent carbon atoms form a spiro or fused C_{3-6}cycloalkyl or 4 to 6 membered heterocyclyl ring.


11. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A' is selected from the group consisting of cyclopentyl, tetrahydrofuranyl, cyclohexyl and tetrahydropyranyl; each of which is optionally fused with a C_{3-6}cycloalkyl ring.


12. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein A' is selected from the group consisting of cyclopentyl, tetrahydrofuranyl, cyclohexyl and tetrahydropyranyl; each of which is optionally fused with a cyclopropyl group.


13. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^2 is H.


14. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein  is selected from the group consisting of:





 and .

15. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein  is selected from the group consisting of:



 and .

16. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein  is selected from the group consisting of:




and .

















17. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is phenyl substituted with two or three R^5 groups, wherein each R^5 is independently selected from the group consisting of halogen and C_{1-3}alkyl.

18. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is phenyl substituted with two or three R^5 groups, wherein each R^5 is independently selected from the group consisting of fluoro and chloro.
















19. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of:



20. The compound of claim 1 selected from the group consisting of:

















and


or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound of any one of claims 1–20, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

22. The pharmaceutical composition of claim 21, further comprising a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent selected from the group consisting of emtricitabine and lamivudine.

23. Use of a compound of any one of claims 1–20 or a pharmaceutical composition of claim 21 or 22 in the manufacture of a medicament for treating an HIV infection in a human having or at risk of having the infection.

24. The use of claim 23 wherein the medicament further comprises a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent selected from the group consisting of emtricitabine and lamivudine.

25. The use of claim 23 wherein the medicament is for co-administration with a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent selected from the group consisting of emtricitabine and lamivudine.